These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37155250)

  • 1. Lenacapavir (Sunlenca) for multidrug-resistant HIV.
    Med Lett Drugs Ther; 2023 May; 65(1675):68-70. PubMed ID: 37155250
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenacapavir: A novel injectable HIV-1 capsid inhibitor.
    Hitchcock AM; Kufel WD; Dwyer KAM; Sidman EF
    Int J Antimicrob Agents; 2024 Jan; 63(1):107009. PubMed ID: 37844807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV.
    Prather C; Lee A; Yen C
    Am J Health Syst Pharm; 2023 Dec; 80(24):1774-1780. PubMed ID: 37767713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options.
    Tuan J; Ogbuagu O
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):565-570. PubMed ID: 37067160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy.
    Cluck DB; Chastain DB; Murray M; Durham SH; Chahine EB; Derrick C; Dumond JB; Hester EK; Jeter SB; Johnson MD; Kilcrease C; Kufel WD; Kwong J; Ladak AF; Patel N; Pérez SE; Poe JB; Bolch C; Thomas I; Asiago-Reddy E; Short WR
    Pharmacotherapy; 2024 May; 44(5):360-382. PubMed ID: 38853601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenacapavir: First Approval.
    Paik J
    Drugs; 2022 Sep; 82(14):1499-1504. PubMed ID: 36272024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary.
    Cluck DB; Chastain DB; Murray M; Durham SH; Chahine EB; Derrick C; Dumond JB; Hester EK; Jeter SB; Johnson MD; Kilcrease C; Kufel WD; Kwong J; Ladak AF; Patel N; Pérez SE; Poe JB; Bolch C; Thomas I; Asiago-Reddy E; Short WR
    Pharmacotherapy; 2024 May; 44(5):354-359. PubMed ID: 38853605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibalizumab-uiyk (Trogarzo) for multidrug-resistant HIV.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):68-69. PubMed ID: 29667947
    [No Abstract]   [Full Text] [Related]  

  • 9. Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
    Dvory-Sobol H; Shaik N; Callebaut C; Rhee MS
    Curr Opin HIV AIDS; 2022 Jan; 17(1):15-21. PubMed ID: 34871187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus.
    Chatzidaki I; Curteis T; Luedke H; Mezzio DJ; Rhee MS; McArthur E; Eddowes LA
    Value Health; 2023 Jun; 26(6):810-822. PubMed ID: 36566886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection.
    Blair HA
    Drugs; 2020 Feb; 80(2):189-196. PubMed ID: 31970712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibalizumab.
    Bettiker RL; Koren DE; Jacobson JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):354-358. PubMed ID: 29746266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
    Segal-Maurer S; DeJesus E; Stellbrink HJ; Castagna A; Richmond GJ; Sinclair GI; Siripassorn K; Ruane PJ; Berhe M; Wang H; Margot NA; Dvory-Sobol H; Hyland RH; Brainard DM; Rhee MS; Baeten JM; Molina JM;
    N Engl J Med; 2022 May; 386(19):1793-1803. PubMed ID: 35544387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1.
    Anderson SJ; van Doornewaard A; Turner M; Jacob I; Clark A; Browning D; Schroeder M
    Clin Ther; 2022 Jun; 44(6):886-900. PubMed ID: 35610081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenacapavir (Sunlenca®) for the treatment of HIV-1.
    Patel PC; Beasley HK; Hinton A; Wanjalla CN
    Trends Pharmacol Sci; 2023 Aug; 44(8):553-554. PubMed ID: 37330326
    [No Abstract]   [Full Text] [Related]  

  • 16. A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV.
    Beran C; Duggan JM; Sahloff EG
    J Pharm Technol; 2024 Aug; 40(4):194-201. PubMed ID: 39157636
    [No Abstract]   [Full Text] [Related]  

  • 17. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.
    Beccari MV; Mogle BT; Sidman EF; Mastro KA; Asiago-Reddy E; Kufel WD
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus.
    Lee NE; Sutherland RK
    Curr Opin Infect Dis; 2023 Feb; 36(1):15-19. PubMed ID: 36753704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
    Gupta SK; Berhe M; Crofoot G; Benson P; Ramgopal M; Sims J; McDonald C; Ruane P; Sanchez WE; Scribner A; Liu SY; VanderVeen LA; Dvory-Sobol H; Rhee MS; Baeten JM; Koenig E
    Lancet HIV; 2023 Jan; 10(1):e15-e23. PubMed ID: 36566079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
    Jacobson JM; Kuritzkes DR; Godofsky E; DeJesus E; Larson JA; Weinheimer SP; Lewis ST
    Antimicrob Agents Chemother; 2009 Feb; 53(2):450-7. PubMed ID: 19015347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.